Rhabdomyolysis associated with quinacrine therapy in a patient with chronic cutaneous lupus erythematosus.
We describe a patient who developed rhabdomyolysis 6 weeks after starting combination therapy with hydroxychloroquine and quinacrine for the treatment of chronic cutaneous lupus erythematosus (CCLE). Myopathy due to 4-aminoquinolone antimalarials has been well documented. It is plausible that quinacrine may induce muscle injury in a manner similar to other antimalarials but, to our knowledge, rhabdomyolysis associated with antimalarial therapy has not been reported.
Creel
Naomi
N
Department of Dermatology, Walter Reed Army Medical Center, Washington, DC, USA.
Werth
Victoria
V
D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000008:administration & dosage; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy*; D008875:Middle Aged; D011796:Quinacrine / Q000008:administration & dosage / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced*
D006886:Hydroxychloroquine; D011796:Quinacrine